Quest Diagnostics (DGX) EBITDA Margin (2009 - 2026)
Quest Diagnostics' (DGX) quarterly EBITDA Margin came in at 15.08% in Q2 2026, down 78.0% year-over-year from 68.56% in Q2 2025, and up 9.44% quarter-over-quarter from 13.78% in Q1 2026.
Powered by 
Analysis
Quest Diagnostics (DGX) EBITDA Margin (2009 - 2026) Analysis & Trends
Quest Diagnostics has disclosed EBITDA Margin across 18 years of filings, most recently posting 15.08% for Q2 2026.
- In Q2 2026, EBITDA Margin fell 78.0% year-over-year to 15.08%; the TTM figure through Jun 2026 stood at 14.1% (up 8.0% YoY), while the FY2025 annual figure was 14.1%, up 47.0% from the prior year.
- EBITDA Margin came in at 15.08% for Q2 2026 at Quest Diagnostics, up from 13.78% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 19.65% in Q1 2022 to a low of 5.79% in Q4 2022.
- Average EBITDA Margin over 5 years is 13.96%, with a median of 13.78% recorded in 2024.
- Year-over-year, EBITDA Margin plunged 1375 bps in 2022 and surged 588 bps in 2023.
- Over 5 years, EBITDA Margin stood at 5.79% in 2022, then surged by 102 bps to 11.67% in 2023, then grew by 18 bps to 13.77% in 2024, then declined by 0 bps to 13.76% in 2025, then climbed by 10 bps to 15.08% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 15.08% in Q2 2026, 13.78% in Q1 2026, and 13.76% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Natera | 49.39 Bn | 48.29 Bn | 486.15 Mn | -10.07% |
| 2 | Quest Diagnostics | 27.49 Bn | 26.86 Bn | 1.03 Bn | 15.08% |
| 3 | Labcorp Holdings | 26.51 Bn | 26.37 Bn | 1.11 Bn | 12.10% |
| 4 | Guardant Health | 23.17 Bn | 22.12 Bn | 219.03 Mn | -38.55% |
| 5 | Tempus AI | 12.59 Bn | 11.77 Bn | 274.25 Mn | -19.85% |
| 6 | Caris Life Sciences | 8.01 Bn | 7.22 Bn | 182.38 Mn | 10.21% |
| 7 | Sotera Health | 5.53 Bn | 5.17 Bn | 177.96 Mn | 34.17% |
| 8 | BillionToOne | 4.80 Bn | 4.25 Bn | 77.11 Mn | 5.03% |
| 9 | Adaptive Biotechnologies | 4.40 Bn | 4.05 Bn | 51.39 Mn | -22.04% |
| 10 | iRhythm Holdings | 3.68 Bn | 3.08 Bn | 163.21 Mn | -1.13% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.08% |
| Mar 31, 2026 | 13.78% |
| Dec 31, 2025 | 13.76% |
| Sep 30, 2025 | 13.71% |
| Jun 30, 2025 | 15.86% |
| Mar 31, 2025 | 13.05% |
| Dec 31, 2024 | 13.77% |
| Sep 30, 2024 | 13.26% |
| Jun 30, 2024 | 14.81% |
| Mar 31, 2024 | 12.68% |
| Dec 31, 2023 | 11.67% |
| Sep 30, 2023 | 14.90% |
| Jun 30, 2023 | 14.88% |
| Mar 31, 2023 | 13.08% |
| Dec 31, 2022 | 5.79% |
| Sep 30, 2022 | 15.77% |
| Jun 30, 2022 | 15.82% |
| Mar 31, 2022 | 19.65% |
| Dec 31, 2021 | 19.53% |
| Sep 30, 2021 | 23.50% |